Cell Therapeutics to Submit New XYOTAX Drug Trial to FDA

| 10 Dec 2006 | Posts | 1,441 views

Cell Therapeutics announced on Friday that it will close a XYOTAX drug trial, known as PIONEER, to submit a new trial protocol to the Food and Drug Administration (FDA). The new protocol will be known as PGT306 and will be submitted to the FDA by year’s end.

Because of the particularly low death rate among women patients during the trial, CTIC wants to focus its research on women with normal estogen levels. CEO Dr. James Bianco hopes that this group will be able to increase its uptake and metabolism of the chemotherapeutic drug because of estrogen.

Shares of CTIC dipped 2.2% to $1.86 on 8 December 2006.

Share chart of CTIC

Related posts:

Cell Therapeutics To Suspend Enrollment for PIONEER Drug Trial
http://glob.lokety.com/2006/11/cell-therapeutics-to-suspend.html>

Cell Therapeutics Signs Deal With Norvatis
http://glob.lokety.com/2006/09/cell-therapeutics-signs-deal-with.html>

Cell Therapeutics Up After Positive Xyotax Phase 1 Results
http://glob.lokety.com/2006/08/cell-therapeutics-up-after-positive.html>

Cell Therapeutics Signs Financing Agreement
http://glob.lokety.com/2006/06/cell-therapeutics-signs-financing.html>

Technorati Tags: , , , , , , ,

Share

Related posts:

:, , Subscribe


Leave a Reply

Archives

Be Good

View Teng-Yan Loke's profile on LinkedIn

The Hunger Site

Counter visits since 16 Sep 2006

Technology Blogs - BlogCatalog Blog Directory